Result of AGM
RNS & Investor News
License and supply agreement with Genuine Health
18 November 2020
LPLDL® license for Canada and USA
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that its wholly-owned
subsidiary, ProBiotix Health Ltd. ("ProBiotix"), has granted a non-exclusive LPLDL® license to Genuine Health Inc. ("Genuine Health") for a cardiovascular health product in Canada and the USA.
Genuine Health (https://www.genuinehealth.com/en-ca/) is an established Canadian natural health company that has been formulating natural products for more than 25 years.
The company makes greens+, omegas, proteins and probiotics. Genuine Health's greens+ is the #1 superfood in Canada and the only superfood to be validated by nine clinical studies as reported on their website. The Genuine Health website
also states that it specialises in natural, science based, clinically proven products with ingredients which create product differentiation in the North American market.
As part of the agreement, Genuine Health will submit products containing LPLDL® for cardiovascular and other health claims to Health Canada, a department of the Government of Canada responsible for the country's federal health policy. The Company believes that if registration is successful LPLDL® will be the first probiotic supplement in the Canadian market to obtain a specific health claim for cardiovascular health.
This agreement is another step in building brand and product presence in the large North American market as a dietary supplement, a live biotherapeutic product (LBP), or a functional ingredient. The agreement is for an initial period of 36 months.
Mikkel Hvid-Hansen, Commercial Director of ProBiotix Health commented: "We are pleased to have signed an agreement with Genuine Health in such a large and important market for probiotic products. We believe working
with Genuine Health creates a unique opportunity to achieve a probiotic health claim for cardiovascular health and provide further product differentiation in the North American market. We see this as another step in building revenues and market presence of LPLDL® inside a wide range of products, presented in different presentations and formulations, for cardiovascular health in both consumer and pharmaceutical markets around the world."
Stewart Brown, Founder and CEO of at Genuine Health, commented: "We are excited to work towards introducing innovative and science-backed products into the North American market through our relationship with ProBiotix. The ProBiotix team continue to produce cutting edge research surrounding the link between probiotics (LPLDL®) and cardiovascular health. This makes them a great partner in our mission to create products that promote whole-body health and wellness, with a particular focus on the powerful role of the microbiome. We look forward to a long and successful partnership with ProBiotix Health."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
The Directors of the Company accept responsibility for the content of this announcement
For further information, please contact:
OptiBiotix Health plc
Stephen O'Hara, Chief Executive
Contact via Walbrook below
Cairn Financial Advisers LLP (NOMAD)
Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Walbrook PR Ltd
Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and
OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare
supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identiﬁed by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding OptiBiotix's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reﬂect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.
OptiBiotix Health secures significant exclusive licence agreement for OptiBiome
Stephen O'Hara | 01 Apr 2020